Tag: Replimune

The coming weeks represent a critical juncture for Replimune Group Inc., with a key regulatory decision and a series of ...

The clinical-stage biotech firm Replimune is advancing its lead therapeutic candidate with a clear emphasis on navigating regulatory requirements. The ...

Replimune Group Inc. is approaching a pivotal sequence of events that will shape its future. The biopharmaceutical company’s shares last ...

A dramatic financial confrontation is unfolding around Replimune Group, where hedge funds betting against the company face off against institutional ...

For Replimune and its investors, 2026 is shaping up to be a defining period. After a significant regulatory setback in ...

Replimune Group Inc. has received a substantial confidence boost from regulators, with the U.S. Food and Drug Administration accepting the ...

Biotechnology firm Replimune witnessed a dramatic surge in its share price following a significant regulatory development. The substantial upward movement, ...

Replimune Group Inc. finds itself navigating turbulent waters as multiple challenges converge. The biotechnology firm faces substantial headwinds from regulatory ...

Replimune Group Inc. finds itself navigating turbulent market conditions as its stock value experiences a dramatic collapse. The biotechnology firm ...

Replimune Group Inc. finds itself in a severe crisis, battling significant regulatory setbacks and a growing wave of shareholder litigation. ...